Michael H. Mulroy
Known title: DirectorCIK: 0001509725
Michael H. Mulroy's purchase track record
Michael H. Mulroy has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2024 | LCTX | $23K | +36.0% | +40.0% | -2.8% |
| 3/24/2022 | LCTX | $10K | -6.3% | -18.1% | -16.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LCTX | ▲ Buy | Open Market | 40,000 | $23K | 11/22/2024 | View on chart |
| LCTX | ▲ Buy | Open Market | 7,000 | $10K | 3/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
LCTX Holds Q2 2026 Earnings Conference Call
Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.
LCTX Holds Q2 2026 Earnings Conference Call. Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.